Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease.

aortic regurgitation aortic stenosis heart failure with preserved ejection fraction heart failure with reduced ejection fraction left heart disease mitral regurgitation mitral stenosis pulmonary hypertension valvular heart disease

Journal

JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241

Informations de publication

Date de publication:
24 Jun 2024
Historique:
received: 03 08 2023
revised: 04 03 2024
accepted: 08 04 2024
medline: 6 7 2024
pubmed: 6 7 2024
entrez: 6 7 2024
Statut: aheadofprint

Résumé

Pulmonary hypertension associated with left heart disease (PH-LHD) remains the most common cause of pulmonary hypertension globally. Etiologies include heart failure with reduced and preserved ejection fraction and left-sided valvular heart diseases. Despite the increasing prevalence of PH-LHD, there remains a paucity of knowledge about the hemodynamic definition, diagnosis, treatment modalities, and prognosis among clinicians. Moreover, clinical trials have produced mixed results on the usefulness of pulmonary vasodilator therapies for PH-LHD. In this expert review, we have outlined the critical role of meticulous hemodynamic evaluation and provocative testing for cases of diagnostic uncertainty. Therapeutic strategies-pharmacologic, device-based, and surgical therapies used for managing PH-LHD-are also outlined. PH-LHD in advanced heart failure, and the role of mechanical circulatory support in PH-LHD is briefly explored. An in-depth understanding of PH-LHD by all clinicians is needed for improved recognition and outcomes among patients with PH-LHD.

Identifiants

pubmed: 38970588
pii: S2213-1779(24)00436-0
doi: 10.1016/j.jchf.2024.04.031
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Onyedika J Ilonze (OJ)

Division of Cardiovascular Medicine, Krannert Cardiovascular Research Center, Indiana University, Indianapolis, Indiana, USA. Electronic address: oilonze@iu.edu.

Imo A Ebong (IA)

Division of Cardiology, University of California Davis, Sacramento, California, USA.

Maya Guglin (M)

Division of Cardiovascular Medicine, Krannert Cardiovascular Research Center, Indiana University, Indianapolis, Indiana, USA.

Ajith Nair (A)

Winters Center for Heart Failure Research, Michael E. DeBakey VA Medical Center, Texas Heart Institute, Baylor College of Medicine, Houston, Texas, USA.

Jonathan Rich (J)

Division of Cardiology, Bluhm Cardiovascular Institute Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Vallerie McLaughlin (V)

University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, USA.

Ryan J Tedford (RJ)

Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.

Sula Mazimba (S)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, Virginia, USA; AdventHealth, Orlando, Florida, USA.

Classifications MeSH